Nuevocor

Nuevocor: Tackling Untreatable Heart Conditions Through T-Up “T-Up allowed us to access the deep pool of talent that resides within A*STAR. Companies looking to strengthen their teams can consider tapping into this programme to gain access to individuals who have an interest in contributing to the local R&D ecosystem.” - Dr Yann Chong Tan, CEO and Co-founder of Nuevocor Through A*STAR’s Technology for Enterprise Capability Upgrading (T-Up) Programme, Nuevocor is tackling some of the most challenging, untreatable heart conditions. By collaborating with scientists like Giulia Varsano from A*STAR Institute of Molecular and Cell Biology (IMCB), Nuevocor is accelerating the development of innovative therapies that target rare genetic heart diseases. Read the full story to find out how.  Interested in A*STAR’s T-Up programme? Connect with us at SME Tech Day 2024: https://lnkd.in/g8ztAhgM #ASTARforEnterprise #InnovatewithASTAR #Innovation 

We are pleased to share that Dr Yann Chong Tan, Chief Executive Officer and co-founder of Nuevocor, will be delivering an oral presentation titled “NVC-001 – an AAV gene therapy for LMNA-related dilated cardiomyopathy” at the European Society for Gene and Cell Therapy #ESGCT 31st Annual Congress on 22 – 25 October 2024, La Nuvola, Rome. The presentation is scheduled on 24 October 2024 during Session 7c: Cardio and Muscular between 9.00am to 11.00am. 

Good to be in NYC with John Lee MD PhD at the Chardan conference. Looking forward to catching up with old friends, meeting new ones, and having some good discussions!

We are pleased to announce that we won the Most Promising Gene Therapy Pipeline in APAC at the Asia Pacific Cell & Gene Therapy Excellence Awards 2024. Winners are decided through voting by the public. The APAC Cell & Gene Therapy Excellence Awards was held in conjunction with the 8th Annual Cell & Gene Therapy World Asia 2024. Jia Min Loo, our Senior Director, Discovery was one of the invited speakers at the conference, where he gave a presentation on our Lead Program, NVC-001 for LMNA Dilated Cardiomyopathy, a genetic cardiomyopathy with great unmet need.

Very privileged to receive this award on behalf of the team at Nuevocor. This recognition would not have been possible without the hard work put in by the team over the last few years. Thank you all!

We are pleased to share that our Chief Executive Officer and co-founder, Dr. Yann Chong Tan, and our Chief Medical Officer, Dr. John Lee, are attending #Chardan’s invite-only 8th Annual Genetic Medicines Conference held at The Westin Grand Central, New York City from September 30 to October 1, 2024, where we will give a presentation on Nuevocor on 1 October 2024 from 2.30PM to 3.00PM.  In addition, our CEO Dr. Tan is an invited panelist on the panel session titled “Getting to the heart of the matter: genetic medicines for cardiac diseases”. The panel session is scheduled for 1 October 2024 from 12.10PM to 1.00PM.  

We are pleased to announce that we won the Most Promising Gene Therapy Pipeline in APAC at the Asia Pacific Cell & Gene Therapy Excellence Awards 2024. Winners are decided through voting by the public. The APAC Cell & Gene Therapy Excellence Awards was held in conjunction with the 8th Annual Cell & Gene Therapy World Asia 2024. Jia Min Loo, our Senior Director, Discovery was one of the invited speakers at the conference, where he gave a presentation on our Lead Program, NVC-001 for LMNA Dilated Cardiomyopathy, a genetic cardiomyopathy with great unmet need.